Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    Leaky Gut Linked to HIV in Brain, Dementia - (DGNews)
    TopAbstracts in AIDS and HIV 08/18/2008 - (DGNews)
    HIV Patients Resistant to Non-Nucleoside Reverse Transcriptase Inhibitors Experience Superior Results With Etravirine: Presented at AIDS 2008 - (DGDispatch)
    Outcome Data Disputed in Abacavir/Lamivudine Comparison Trial: Presented at AIDS 2008 - (DGDispatch)
    HIV Patients With High Viral Load Worsen on Fixed-Dose Abacavir/Lamivudine Compared With Fixed-Dose Tenofovir/Emtricitabine: Presented at AIDS 2008 - (DGDispatch)

    News archive

     Recent webcasts/CME - AIDS and HIV
    Boosting Adherence and Managing Antiretroviral Drug Adverse Events: The Role of the Community Pharmacist
    Pharmacotherapy for Pediatric HIV Infection

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Salmonella Enteritidis Meningitis in a First Time Diagnosed AIDS Patient: Case Report
      Pediatric Patient with Systemic Lupus Erythematosus and Congenital Acquired Immunodeficiency Syndrome: An Unusual Case and a Review of the Literature
      Giant Pyogenic Granuloma of the Thigh: A Case Report
      Acute Renal Failure in an AIDS Patient on Tenofovir: A Case Report
      Atypically Distributed Cutaneous Lesions of Norwegian Scabies in an HIV-Positive Man in South India: A Case Report

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      First Head-to-Head Comparison of Tenofovir/Emtricitabine Versus Abacavir/Lamivudine in HIV Patients With Virologic Suppression: Presented at IAS

        By Rachel Parratt

        SYDNEY, AUSTRALIA -- July 26, 2007 -- KivexaŽ (abacavir/lamivudine) met noninferiority criteria for virologic efficacy but not for treatment efficacy when compared with TruvadaŽ (tenofovir/emtricitabine).

        Jose Gatell, MD, Professor of Medicine, University of Barcelona, and Head, Infectious Diseases Unit, University Hospital Clinic, Barcelona, Spain, presented these findings here at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention.

        Truvada and Kivexa are fixed-dose combinations and the most commonly recommended and used nucleoside analogue backbone for initial antiretroviral therapy.

        A total of 333 patients with virologic suppression for at least 6 months while on a lamivudine-containing highly active antiretroviral therapy regimen had their nucleoside reverse transcriptase inhibitor (NRTI) backbone switched to either Truvada or Kivexa.

        Virologic suppression was defined as an HIV RNA level <200 copies/mL.

        Treatment failure occurred in 13.3% of patients in the Truvada arm and 19.2% of patients in the Kivexa arm.

        For treatment efficacy, the Kivexa arm did not meet the noninferiority endpoint compared with the Truvada arm. This difference was mainly driven by nine patients in the Kivexa arm who discontinued because of suspected abacavir hypersensitivity. Retrospective human leukocyte antigen (HLA) testing showed three out of the nine patients were HLA B5701 positive.

        For virologic efficacy, Kivexa met the noninferiority endpoint compared with Truvada. However, there were more virologic failures in the Kivexa arm compared with the Truvada arm (2.4% vs 0%).

        Dr. Gatell commented, "In patients switching the NRTI component to Kivexa versus Truvada, noninferiority was met for virologic efficacy, but not for treatment efficacy."

        [Presentation title: Efficacy and Safety of NRTI's Switch to Tenofovir Plus Emtricitabine (TruvadaŽ) Vs. Abacavir Plus Lamivudine (KivexaŽ) in Patients With Virologic Suppression Receiving a Lamivudine Containing HAART: The BICOMBO Study. Late Breaker WESS102]




      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send